Global Hunter Securities Starts Cubist Pharmaceuticals (CBST) at Neutral; Solid Execution vs. Long-Term Pressures
Tweet
Share
E-mailGet Alerts CBST Hot Sheet
Price: $101.94 --0%
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Global Hunter Securities initiates coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with a Neutral. Valuation range $35-44.
Global analyst said, "Cubist is a key player in the infectious disease space, focused on the development of novel antibiotics. The company’s marketed drug, Cubicin, is approved for complicated skin and skin structure infections caused by certain Gram-positive bacteria, and bloodstream infections (bacteremia) caused specifically by Staphylococcus aureus. We are believers in Cubicin’s position as a leading option for serious Gram-positive infections, and expect sales to ramp nicely over the next five to seven years, potentially achieving the company’s stated $1B sales outlook. However, we believe that current trading levels largely incorporate this outlook. In our view, to sustain growth beyond 2017/18, several important developments must work solidly in the company’s favor. Our Neutral rating reflects current valuation as well as our cautious outlook on the probability that all of the required events will fall into place without a hitch. However, we believe successful navigation of these risks could lead to upside."
For more ratings news on Cubist Pharmaceuticals click here and for the rating history of Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $38.30 yesterday.
Global analyst said, "Cubist is a key player in the infectious disease space, focused on the development of novel antibiotics. The company’s marketed drug, Cubicin, is approved for complicated skin and skin structure infections caused by certain Gram-positive bacteria, and bloodstream infections (bacteremia) caused specifically by Staphylococcus aureus. We are believers in Cubicin’s position as a leading option for serious Gram-positive infections, and expect sales to ramp nicely over the next five to seven years, potentially achieving the company’s stated $1B sales outlook. However, we believe that current trading levels largely incorporate this outlook. In our view, to sustain growth beyond 2017/18, several important developments must work solidly in the company’s favor. Our Neutral rating reflects current valuation as well as our cautious outlook on the probability that all of the required events will fall into place without a hitch. However, we believe successful navigation of these risks could lead to upside."
For more ratings news on Cubist Pharmaceuticals click here and for the rating history of Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $38.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Starts LunR Royalties Corp (LUNR:CN) at Buy
- Jefferies Starts Eldorado Gold Corp (EGO) at Buy
- Baird Starts Hubbell (HUBB) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
